Merged with adjuvant AddaVax, the VLPs significantly prolonged survival time and heightened IFN‐γ’s secretion of T cells in mammary carcinoma cell‐burden mice.[80] These findings show that the combination of VLPs with tumor antigens is feasible, suggesting that tumor membrane combination with VLPs for tumor vaccination is effective. Here, IFNG is linked to neoplasm.